Browse all clinical evidence, news, and expert commentary
Most of us carry a mental model of fatty liver disease as something that turns up more often in men. A new narrative review in Diabetologia suggests it's time for an update.
A recent UK survey reported that 37.7% of clinicians have never had any teaching on vulval skin disease, and 97.5% wanted clear diagnostic criteria.
NICE has made the most significant update to ovarian cancer detection guidance since NG12 was first published. Here's what you need to know.
The SCOUT trial is the first pragmatic head-to-head comparison of all four commonly used UTI regimens in a single trial. The results reinforce rather than redraw the UK prescribing picture — but they do sharpen one key question for primary care.
From raised LDL to a new non-hormonal drug class and the largest HRT safety study to date, this week is all menopause in primary care.
NICE has now recommended the first drug in a genuinely new class — Fezolinetant in TA1143. It's an NK3 receptor antagonist for moderate to severe menopausal vasomotor symptoms when HRT isn't suitable.
No excess mortality after 14 years. No signal for cardiovascular or cancer deaths; plus a survival benefit in women after bilateral oophorectomy.
Individualised HRT offers substantial symptomatic relief with acceptable safety when used appropriately; however, ongoing research is needed to address persistent uncertainties about long-term outcomes.
